ABIOMED

ABIOMED EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ABIOMED (ABMD) as of Nov 7, 2026 is 140.72 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 229.56 M USD — a change of -38.70% (lower).

EBITDA

140.72 MUSD

YoY

-38.70%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ABIOMED is 2022 140.72 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ABIOMED was 2021 229.56 M USD. It decreases by -38.70% lower compared to the previous year.

The ABIOMED EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
28.67 M USD
Jan 1, 2016
65.10 M USD
Jan 1, 2017
90.14 M USD
Jan 1, 2018
157.14 M USD
Jan 1, 2019
224.81 M USD
Jan 1, 2020
249.22 M USD
Jan 1, 2021
229.56 M USD
Jan 1, 2022
140.72 M USD
The ABIOMED EBITDA history
YEAREBITDAYoY
140.72 MUSD-38.70%
229.56 MUSD-7.89%
249.22 MUSD+10.86%
224.81 MUSD+43.07%
157.14 MUSD+74.33%
90.14 MUSD+38.45%
65.10 MUSD+127.11%
28.67 MUSD+242.77%
8.36 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABIOMED Stock analysis

What does ABIOMED do? Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ABIOMED stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ABIOMED is 140.72 M USD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ABIOMED changed from 229.56 M USD to 140.72 M USD, representing a -38.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ABIOMED since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ABIOMED historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ABIOMED

All Key Metrics — ABIOMED